ZyVersa Therapeutics, Inc. (ZVSA): Nasdaq/NYSE listing notice — ZyVersa Therapeutics receives approval to transfer stock listing from Nasdaq Global Market to Capital Market

ZyVersa Therapeutics, Inc.

Received Nasdaq approval on Feb 29, 2024 to transfer listing from Global Market to Capital Market.
Transfer effective as of open of business on March 1, 2024; ticker ZVSA unchanged.
Cures prior deficiency in minimum Market Value of Publicly Held Shares (MVPHS) requirement.
Company had 7,583,863 shares of common stock outstanding as of March 1, 2024.
Nasdaq Capital Market has similar corporate governance requirements but different listing standards.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ZyVersa Therapeutics, Inc. received a nasdaq compliance regained notice regarding market value (rules 5450(b)(1)(C)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: market value
Rules: 5450(b)(1)(C)

Exact text from the filing

February 29, 2024, the Company received approval from Nasdaq to transfer the listing of the Company’s Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s Common Stock will be transferred to the Nasdaq Capital Market effective as of the open of business on March 1, 2024, and will continue to trade under the symbol “ZVSA.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. As of

View on SEC.gov

Browse all listing & compliance notices →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-008508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.